



Effect of repeated mass drug administration with praziquantel and track and treat of taeniosis cases on the prevalence of taeniosis in *Taenia solium* endemic rural communities of Tanzania

Braae, Uffe Christian; Magnussen, Pascal; Ndawi, Benedict; Wendy, Harrison; Lekule, F.P.; Johansen, Maria Vang

Published in:
Acta Tropica

DOI:
[10.1016/j.actatropica.2015.10.012](https://doi.org/10.1016/j.actatropica.2015.10.012)

Publication date:
2017

Document version
Early version, also known as pre-print

Citation for published version (APA):
Braae, U. C., Magnussen, P., Ndawi, B., Wendy, H., Lekule, F. P., & Johansen, M. V. (2017). Effect of repeated mass drug administration with praziquantel and track and treat of taeniosis cases on the prevalence of taeniosis in *Taenia solium* endemic rural communities of Tanzania. *Acta Tropica*, 165, 246-251.
<https://doi.org/10.1016/j.actatropica.2015.10.012>

1 **Manuscript for Acta Tropica**

2 **Title:** Effect of repeated mass drug administration with praziquantel and track and treat of taeniosis
3 cases on the prevalence of taeniosis in *Taenia solium* endemic rural communities of Tanzania

4 Uffe Christian Braae ^{1,*}, Pascal Magnussen ^{1,2}, Benedict Ndawi ³, Wendy Harrison ⁴, Faustin
5 Lekule ⁵, Maria Vang Johansen ¹

6 **Affiliations:** **1** Section for Parasitology and Aquatic Diseases, Department of Veterinary Disease
7 Biology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-1870
8 Frederiksberg, Denmark, **2** Centre for Medical Parasitology, Faculty of Health of Medical Sciences
9 University of Copenhagen, DK-1353 Copenhagen, Denmark, **3** Bora Professional Consultancy
10 Services, Iringa, Tanzania, **4** Faculty of Medicine, School of Public Health, Imperial College
11 London, United Kingdom, **5** Faculty of Agriculture, Sokoine University of Agriculture, Morogoro,
12 Tanzania

13 * **Corresponding author:** Uffe Christian Braae, Section for Parasitology and Aquatic Diseases,
14 Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of
15 Copenhagen, DK-1870 Frederiksberg, Denmark. E-mail address: braae@sund.ku.dk

16

17 **Abstract**

18 This study evaluated the effect of mass drug administration (MDA) with praziquantel administered
19 to school-aged children (SAC) combined with ‘track and treat’ of taeniosis cases in the general
20 population on the copro-antigen (Ag) prevalence of taeniosis. The study was conducted in 14
21 villages in Mbozi and Mbeya district, Tanzania. SAC made up 34% of the population and received
22 MDA with praziquantel (40 mg/kg) in 2012 (both districts) and in 2013 (Mbozi only). Three cross-

23 sectional population-based surveys were performed in 2012 (R0), 2013 (R1), and 2014 (R2). In
24 each survey approximately 3,000 study subjects of all ages were tested for taeniosis using copro-
25 Ag-ELISA. In total 9,064 people were tested and copro-Ag-ELISA positive cases were offered
26 treatment 6-8 months after sampling. The copro-Ag prevalence of taeniosis was significantly higher
27 (X^2 -test, $p=0.007$) in Mbozi (3.0%) at R0 compared to Mbeya (1.5%). Twelve months after MDA
28 in both districts (R1), the copro-Ag prevalence had dropped significantly in both Mbozi (2.0%,
29 $p=0.024$) and in Mbeya (0.3%, $p=0.004$), but the significant difference between the districts
30 persisted (X^2 -test, $p<0.001$). Ten months after the second round of MDA in Mbozi and 22 month
31 after the first MDA (R2), the copro-Ag prevalence had dropped significantly again in Mbozi (0.8%,
32 $p<0.001$), but had slightly increased in Mbeya (0.5%, $p=0.051$), with no difference between the two
33 districts (X^2 -test, $p=0.51$). The taeniosis cases tracked and treated between round R0 and R2
34 represented 9% of the projected total number of taeniosis cases within the study area, based on the
35 copro-Ag prevalence and village population data. Among SAC in Mbozi, infection significantly
36 decreased at R1 ($p=0.004$, OR 0.12 CI: 0.02-0.41) and R2 ($p=0.001$, OR 0.24, CI: 0.09-0.53) when
37 comparing to R0. In Mbeya infection significant decreased at R1 ($p=0.013$, OR 0.14, CI: 0.02-
38 0.55), but no difference was found for R2 ($p=0.089$), when comparing to R0 among SAC. This
39 study showed that school-based MDA with praziquantel in combination with 'track and treat' of
40 taeniosis cases significantly reduced the copro-Ag prevalence of taeniosis, and that annual MDA
41 was significantly better than single MDA. The persistence of taeniosis cases illustrates that a One
42 Health approach must be emphasized for effective control.

43

44 **Keywords:**

45 Risk factors; Track and treat; *Taenia solium*; Taeniosis; Mass Drug Administration (MDA); Copro-
46 Ag prevalence; Preventive chemotherapy treatment

47

48 **1. Introduction**

49 *Taenia solium* taeniosis/cysticercosis is a growing and persistent problem in most sub-Saharan
50 countries where pigs have been domesticated (Braae et al., 2015). Since humans are the sole
51 definitive host of this zoonotic tapeworm, treatment of individuals with taeniosis is essential in the
52 control of *T. solium* infection. Efficacious control tools for *T. solium* are available, but an algorithm
53 for optimal tool combination for effective control is now needed. No studies assessing the effect of
54 mass drug administration (MDA) with praziquantel on *T. solium* have been performed on the
55 African continent to date. However, MDA campaigns have previously been used to treat humans in
56 Latin America in efforts to control *T. solium*. Most studies have used porcine cysticercosis
57 prevalence as an indicator of effect (Cruz et al., 1989; Garcia et al., 2006; Keilbach et al., 1989),
58 and others have used prevalence of taeniosis as the measure of treatment effect. Diaz-Camacho et
59 al. (1991) reported from Mexico that a reduction from 1% to 0% in taeniosis prevalence based on
60 stool microscopy was seen one year after MDA with praziquantel (10 mg/kg). However, this was
61 based only on four positive individuals at baseline, a detection methodology with low sensitivity,
62 and no control group or statistical analysis. Another study from Mexico using copro-antigen (Ag)-
63 ELISA and stool microscopy showed a borderline significant ($p=0.06$) drop from 1.1% to 0.5% six
64 months after a single round of community wide MDA with praziquantel (5 mg/kg) (Sarti et al.,
65 2000). In this study the prevalence remained at 0.5% 42 months post intervention. However, no
66 comparison with a control group was made. Allan et al. (1997) reported from Guatemala that the

67 prevalence of taeniosis 10 months after MDA with niclosamide (coverage 75%) was, significantly
68 ($p<0.001$) reduced from 3.5% to 1%, based on copro-Ag-ELISA and stool microscopy. However,
69 no control group was included in this study. So far no studies have reported the effect of repeated
70 rounds of MDA.

71

72 Although theoretically controllable (Kyvsgaard et al., 2007) and declared eradicable by the
73 International Task Force for Disease Eradication in 1993, *T. solium* taeniosis/cysticercosis remains
74 a neglected zoonosis. This is not only due to a lack of available resources but also a lack of
75 information about its burden, transmission, and validation of simple intervention packages (WHO,
76 2010). The World Health Organisation (WHO) included *T. solium* cysticercosis as one of major
77 Neglected Tropical Diseases in 2010 and recommended MDA as the primary intervention strategy
78 against taeniosis (WHO, 2010), but to date no large scale taeniosis control programme has been
79 implemented in sub-Saharan Africa.

80

81 The drug praziquantel, which is effective against taeniosis at a dose as low as 5 mg/kg (Pawlowski,
82 1991), is also used in MDA campaigns against schistosomiasis at a dose of 40 mg/kg. Praziquantel
83 is being used extensively in a number of sub-Saharan African countries where schistosomiasis is
84 prevalent. In countries where schistosomiasis and taeniosis are co-endemic there is the possibility to
85 assess the impact on taeniosis of schistosomiasis control programmes using praziquantel. In
86 Tanzania, school-based MDA with praziquantel is carried out as part of the National
87 Schistosomiasis Control Programme (NSCP) in schistosomiasis endemic districts. This study aimed
88 to assess the effect of repeated rounds of school-based MDA with praziquantel (40 mg/kg) in

89 combination with treatment of all taeniosis cases, in two areas co-endemic for *T. solium*
90 taeniosis/cysticercosis and schistosomiasis.

91

92 **2. Methods**

93 **2.1 Study area**

94 The study was carried out in Mbeya and Mbozi districts, Tanzania. The human population in 2012
95 was estimated to be 305,319 in Mbeya district and 446,339 in Mbozi district (URT, 2013a). School-
96 aged children (SAC) and adults were defined as 4-15 years of age and 16 or above, respectively. In
97 Mbozi and Mbeya districts SAC made up 35% and 33% of the total population, respectively (URT,
98 2013b). Both districts are rural areas with high numbers of pigs kept primarily on a smallholder
99 level, with 31,190 pigs in Mbeya district and 117,483 pigs in Mbozi district in 2007/2008 (URT,
100 2012). *Taenia solium* taeniosis/cysticercosis is highly prevalent within the area (Braae et al., 2014;
101 Komba et al., 2013; Mwanjali et al., 2013). No reports of bovine cysticercosis exist from the region
102 and therefore the prevalence of *T. saginata* was expected to be negligible.

103

104 **2.2 Study design and sample size**

105 The NSCP carried out MDA with praziquantel to SAC in both districts between July and September
106 2012 and in Mbozi district only in September 2013. Children not enrolled in school were
107 encouraged to go and get treatment at the schools during the MDA. Following the MDA three
108 community-based cross-sectional surveys were conducted in 14 villages, eight in Mbeya district
109 (total population 20,104) and six in Mbozi district (total population 18,025) (URT, 2013c). These
110 14 villages were purposively selected based on knowledge of porcine cysticercosis presence
111 (Komba et al., 2013), and made up four communities in each district. The first survey (R0) was

112 carried out in February to March 2012, second survey (R1) in July to August 2013, and the last
113 survey (R2) in July to August 2014 (Figure 1). A sample size of approximately 1500 individuals
114 from each district was targeted with all inhabitants willing to participate from each community
115 included, with approximately 375 people from each community. Meetings informing about the
116 study was carried out in each community prior to each survey. Hereafter, the villages were visited
117 and all individuals invited to participate in the study. Different collection points were set up within
118 each village where participants were provided with a plastic container and requested to submit a
119 stool sample. In each district an active “track and treat” strategy was implemented to subsequently
120 treat taeniosis cases with a single dose of 2g niclosamide for adults and 50 mg/kg for children in
121 October 2012 after the first survey and praziquantel (10mg/kg) in March 2014 after the second
122 survey. Since the “track and treat” followed the MDA children found positive for taeniosis could
123 have been treated twice.

124

125 **2.3 Data collection and copro-Ag-ELISA**

126 All study subjects were interviewed and asked to complete a short questionnaire in order to collect
127 information on demographics, latrine availability, recent (12 months) anthelmintic treatments as
128 part of an MDA, and presence of pigs in the household. Each participant provided one stool sample
129 of which one gram of faeces was stored in 10% formalin at room temperature for analysis. Stool
130 samples were analysed for *T. solium/saginata* antigens at the University of Lusaka in Zambia using
131 a copro-Ag-ELISA assay (Allan et al., 1990) with slight modifications (Mwape et al., 2012). The
132 copro-Ag-ELISA assay has been reported to have an approximate sensitivity and specificity of 85%
133 and 92%, respectively (Praet et al., 2013).

134

135 **2.4 Ethical considerations**

136 Ethical approval was obtained from the National Institute for Medical Research (NIMR) reference
137 number NIMR/HQ/R.8a/Vol. IX/1216. The study was also approved by the Imperial College
138 Research Ethics Committee (ICREC), reference no. ICREC_11_3_6. Permission to conduct the
139 study was sought through regional, district, and village authorities. Prior to each survey all study
140 villages within the study area were visited and the community informed about the survey. Members
141 of the community were given the opportunity to ask questions and seek more information about the
142 study. Written informed consent was obtained from all participants after they were informed about
143 the aim, risks, and benefits of the study. Individuals were informed about possible mild adverse
144 effects of treatment such as stomach pain and nausea. If the person was under 18, consent was
145 sought from a parent or guardian following assent from the participant. After each survey, and upon
146 receiving the laboratory results, villages in the study area were visited, and village leaders, school
147 headmasters and head teachers were informed about the results of the survey and copro-Ag-ELISA
148 positive individuals were offered anthelmintic treatment within 6-8 months of sample collection.
149 All people treated were provided with contact numbers of the district health officer and the medical
150 doctor assigned to the treatment, and told to report any adverse events.

151

152 **2.5 Statistical methods**

153 Data were entered into EPI info 7 (<http://wwwn.cdc.gov/epiinfo/7/>) and transferred to an Excel
154 spread sheet (Microsoft Office Excel 2010®) from where it was imported into the statistical
155 programme R (<http://www.r-project.org>). Logistical regression and univariate analyses based on
156 district, were used for the statistical analyses with p-values considered significant if smaller than
157 0.05. Odds ratios (OR) and 95% confidence intervals (CI) are provide for significant factors.

158

159 3. Results

160 3.1 Study population

161 In total 9,064 stool samples were collected, 3,029 at R0, 3,021 at R1, and 3,014 at R2 (Table 1).

162 The overall copro-Ag prevalence of taeniosis in the population of both districts was 2.2% at R0,

163 1.2% at R1, and 0.7% at R2 (Figure 2). Among the study subjects found positive for taeniosis, 62

164 out of 67 and 29 out of 35 were tracked and treated when revisited after R0 and R1, respectively. Of

165 the treated study subjects overall, 27 were from Mbeya district and 64 from Mbozi district. Based

166 on the theoretical number of tapeworm carriers within the study area as the denominator (number of

167 people per village multiplied with taeniosis copro-Ag prevalence) this corresponds to both 9% of all

168 tapeworm carriers treated within each district and overall for both districts.

169

170 Logistic regression including data from the whole study period revealed a drop in infection at R1

171 ($P < 0.001$, OR 0.49, CI: 0.32-0.74) twelve months after the MDA in both districts and at R2 ten

172 months after the second round of MDA in Mbozi and 22 months after the first MDA ($P < 0.001$, OR

173 0.38, CI: 0.22-0.62) when compared to R0 and controlling for age groups (SAC/Adults) and sex.

174 Logistic regression analyses revealed that the risk of being infected with *T. solium* was significantly

175 greater for males than females ($p = 0.004$, OR 1.73, CI: 1.20-2.52). There was also an increased risk

176 for adults compared to SAC throughout the study period ($p < 0.001$, OR 2.39, CI: 1.64-3.50). Living

177 in Mbozi district was associated with a higher risk of taeniosis infection compared to living in

178 Mbeya district ($p < 0.001$, OR 2.35, CI: 1.59-3.53).

179

180 From each of the three questionnaire surveys it was found that 54, 46, and 38 people, respectively,
181 did not have access to a latrine and 606, 460, and 502, respectively, said they were keeping pigs.
182 Neither lack of latrines or presence of pigs at the household could be associated with taeniosis in
183 this study. During the study period there was a large drop in the number of people stating to have
184 seen “worms” in their stool during the last 12 months, from 612 (20%) at R0 and 590 (20%) at R1,
185 to 179 (6%) at R2. However, this could not be associated with infection.

186

187 **3.2 District comparison**

188 Between the two districts univariate analysis show that at baseline (R0), the copro-Ag prevalence of
189 taeniosis was significantly higher (X^2 -test, $p=0.007$) in Mbozi district (3.0%) compared to Mbeya
190 district (1.5%). The copro-Ag prevalence had significantly dropped in both Mbozi district (2.0%,
191 $p=0.024$) and in Mbeya district (0.3%, $p=0.004$) at R1, but the significant difference between the
192 districts persisted (X^2 -test, $p<0.001$). Ten months after the second round of MDA in Mbozi district
193 and 22 month after the first MDA (R2), the copro-Ag prevalence had significantly dropped further
194 in Mbozi district (0.8%, $p<0.001$), but had slightly increased in Mbeya district (0.5%, $p=0.051$). At
195 this time point there was no difference in taeniosis copro-Ag prevalence between the two districts
196 (X^2 -test, $p=0.51$).

197

198 Analysis of the data from Mbozi district using logistic regression showed a decrease in infection at
199 both R1 ($p=0.022$, OR 0.57, CI: 0.35-0.92) and R2 ($p=0.001$, OR 0.33, CI: 0.17-0.62) when
200 compared to R0 and controlling for age groups and sex. The logistic regression further revealed
201 males to be more associated with infection ($p=0.013$, OR 1.75, CI: 1.13-2.74) as well as adults
202 ($p<0.001$, OR 2.84, CI: 1.80-4.55). The same analysis for Mbeya district showed a significant

203 decrease in infection from R0 to R1 ($p=0.004$, OR 0.24, CI: 0.08-0.58) and a significant decrease in
204 infection from R0 to R2 ($p=0.047$, OR 0.42, CI: 0.17-0.96). There was no association found
205 between infection and age groups ($p=0.33$) or sex ($p=0.13$).

206

207 **3.3 School-aged children population comparison**

208 Logistic regression analysis based on stool samples from SAC alone showed that in Mbozi district
209 infection significantly decreased at R1 ($p=0.004$, OR 0.12 CI: 0.02-0.41) and R2 ($p=0.001$, OR
210 0.24, CI: 0.09-0.53) when comparing to R0. There was no association between sex and infection.
211 The same analysis for Mbeya district among SAC showed that infection significant decreased at R1
212 ($p=0.013$, OR 0.14, CI: 0.02-0.55), but no difference was found for R2 ($p=0.089$), when comparing
213 to R0 (Figure 2). There was no difference between sexes. Overall, 95% (35/37) of positive SAC
214 were tracked and treated between R0 and R2. In Mbeya district all positive SAC were tracked and
215 treated after R0 (11/11) and R1 (2/2). In Mbozi district 20 SAC, equivalent to 91% (20/22) of
216 positives, were tracked and treated after R0, and all (2/2) SAC were tracked and treated after R1.
217 Based on the SAC population of the villages and the copro-Ag prevalence found at R0 and R1 this
218 corresponded to 13% of all taeniosis cases within the villages.

219

220 **3.4 Adult population comparison**

221 Focusing on the adult population, logistic regression showed that in Mbozi district there was no
222 difference in infection between R0 and R1 ($p=0.65$) or between R0 and R2 ($p=0.11$). Males were
223 more likely to be infected with a tapeworm ($p=0.019$, OR 1.99, CI: 1.13-3.60) compared to females.
224 In Mbeya district no difference could be seen between infection at survey R1 ($p=0.15$) or R2

225 (p=0.99) compared to R0 (Figure 2). Nor could sex be associated with disease. Overall, 86%
226 (54/63) of positive adults were tracked and treated between R0 and R2. Positive adults were all
227 tracked and treated in Mbeya district after R0 (11/11) and R1 (3/3). In Mbozi district 20, equivalent
228 to 87% (20/23) of the positive adults were tracked and treated after R0, and 22, equivalent to 79%
229 (22/28) of the positive adults were tracked and treated after R1. Based on the adult population of the
230 villages and the copro-Ag prevalence found at R0 and R1 this corresponded to 4% of all taeniosis
231 cases within the villages.

232

233 **4. Discussion**

234 This is, to our knowledge, the first study assessing the effect of MDA of praziquantel on the copro-
235 Ag prevalence of taeniosis in Africa, and the first to assess the effect of repeated MDA. The study
236 showed that school-based MDA with praziquantel in combination with ‘track and treat’ of taeniosis
237 cases significantly reduced the copro-Ag prevalence of taeniosis among SAC. It also demonstrated
238 that annual MDA was significantly more effective in reducing taeniosis copro-Ag prevalence than a
239 single MDA. Although no spill-over effect could be seen into the adult population it is likely that,
240 due to the zoonotic nature of the parasite, this effect would take time to become evident. No
241 measureable effect of ‘track and treat’ was seen in the adult population, and proportionately ‘track
242 and treat’ was less successful in locating cases among the adult population compared to the SAC
243 population.

244

245 The effect of MDA with praziquantel on taeniosis prevalence has been difficult to establish from
246 previous studies due to lack of comparison groups (Carabin and Traoré, 2014). Overall for the
247 entire study population it was not possible to detect a significant difference in copro-Ag prevalence

248 of taeniosis between to two MDA schemes. However, this study showed an effect of school-based
249 MDA in the target population, and when comparing two different treatment schemes, showed
250 annual MDA to be better compared with a single MDA. The copro-Ag prevalence of taeniosis
251 among SAC under the annual MDA remained at a significant lower level compared to baseline (R0)
252 during both follow-up surveys (R1 and R2). The lack of difference found from baseline (R0) to 22
253 months after the MDA (R2) among the SAC that had only received MDA once supported annual
254 MDA being better than a single MDA, but was in contrast to the long-term effect of MDA reported
255 from Latin America by Sarti et al. (2000). It is unknown how fast the parasite returns to pre-
256 treatment levels after intervention has stopped, but according to the model published by Kyvsgaard
257 et al. (2007) it occurs rapidly. In Peru one study tried to estimate the effect of MDA of both humans
258 (praziquantel) and pigs (oxfendazole) (Garcia et al., 2006). The effect was measured based on
259 prevalence and incidence of porcine cysticercosis and the authors concluded that there was a small
260 effect of the MDA, and infection pressure stabilised at decreased rates post treatment. The problem
261 with measuring the effect of MDA on humans based on porcine cysticercosis prevalence is that,
262 treatment might reduce the number of tapeworm carriers, but the environment may stay
263 contaminated for an extended period of time (Ilsoe et al., 1990), diluting the immediate effect of the
264 MDA depending on the transmission rate from the environment to pigs. Incidence of porcine
265 cysticercosis may be a more feasible approach to quantify the environmental contamination
266 (Gonzalez et al., 1994; Ngowi et al., 2008). The drop in reports of “worms” seen in the stool of the
267 study subjects in our study was consistent with the downward trend in taeniosis copro-Ag
268 prevalence, but might also be due to reduction in *Ascaris* infection.

269

270 Although school-based MDA only targets a proportion of the total population, it presents fewer
271 logistical challenges and might be more feasible and in some cases cost-effective compared to

272 community-based MDA. In Mbozi and Mbeya districts SAC constitutes a relatively large
273 proportion (34%) of the general population and might therefore be a cost-effective alternative to
274 community-based MDA. The lack of a measurable spill-over from the school-based MDA, into the
275 adult population could be due to the limited time scale of this study. An important limitation of the
276 study was the low sample size among the adult population towards the end of the study. This
277 resulted in any potential spill-over effect of the school-based MDA into the adult population, being
278 difficult to detect. It was not determined whether a specific SAC had been treated with praziquantel
279 as part of the NSCP, or to what extent the same SAC were repeatedly sampled during the surveys.

280

281 ‘Track and treat’ was successfully carried out, and only few individuals did not receive treatment,
282 the majority of whom were adults. Proportionately, fewer theoretical adult cases (4%) within the
283 study area were treated compared to SAC (13%). No significant decrease in copro-Ag prevalence
284 was seen throughout the study among the adults. This could be due to the small sample size of the
285 last survey (R2). It would be interesting to see if tripling the sample size of adults, thereby
286 increasing the theoretically number of cases treated using ‘track and treat’ from 4% to 12%,
287 reaching the approximate proportion of that in SAC (13%), would yield similar results as was seen
288 among SAC in this study. This may provide a more accurate indication of the potential benefit of
289 MDA versus ‘track and treat’.

290

291 Males were generally found to be more at risk of *T. solium* infection than females in this study.
292 However, this is in contrast to a study from Latin America where females were more likely to have
293 taeniosis (Allan et al., 1996). This difference might be explained by cultural differences that exist

294 between the regions, resulting in differences in risk behaviour among men and women, which
295 influence the transmission of the parasite.

296

297 In Guatemala, Allan et al. (1996) found a peak in taeniosis prevalence among the 30-39 year olds.
298 Similar in this study, the increased risk among adults suggests either increased risk behaviour with
299 age, increased household exposure with repeated infection, or that *T. solium* is long lived meaning
300 prolonged exposure is linked with greater risk of infection. In contrast, the low prevalence of
301 taeniosis suggests that either, the tapeworm has a much shorter life span than anecdotally suggested
302 in the literature, or establishment of infection is a rare event. This could be for two reasons; 1)
303 infected pork with viable cysts is infrequently ingested, or 2) ingested cysts rarely result in
304 establishment of a tapeworm. If the incidence rate of infections is extremely low, then the treatment
305 of positives carried out in both districts after each survey could have great impact on the results and
306 cloud the potential effect of an MDA.

307

308 Pigs or latrine presence and frequency of usage were not associated with infection. Although, these
309 are logical risk factors, the study was restricted since the information was based on questionnaires
310 and not observations which would have given the data more validity. Also, pigs are not slaughtered
311 and consumed within the households, but are traded and consumed at local markets, resulting in
312 general risk to the public consuming pork and not necessarily to the residents of households rearing
313 infected pigs. There was a difference in the ratio of pigs and humans between the two districts, but
314 on a village level the differences are expected to be minuscule, because some villages keep pigs
315 while others do not. Therefore the numbers vary on the district level, but less so on a village level.

316

317 Results from this study demonstrate, for the first time, that repeated administration of praziquantel
318 using a school based approach and part of an established schistosomiasis control programme, can
319 have a significant impact on *T. solium* prevalence. This is an important finding as integration of
320 treatment of neglected diseases will ensure that the limited resources allocated will be used in the
321 most cost-effective manner. Increased availability of donated praziquantel, currently for the
322 treatment of schistosomiasis, could also make a contribution to the control of *T. solium* in the
323 future, but using praziquantel at the dose recommended for schistosomiasis treatment might
324 increase the risk of seizures in people who are suffering from human cysticercosis, and still needs to
325 be evaluated in co-endemic areas (Braae et al., 2015). It is also clear that due to the zoonotic
326 potential of *T. solium*, control and eventually elimination will require a One Health approach
327 consisting of a combination of control tools from both the human and veterinary public health
328 sectors. An algorithm with those control tools is therefore still needed. Further monitoring of
329 prevalence and the establishment of incidence rates of taeniosis in co-endemic areas along with the
330 combination of other control tools should pave the road forward to elimination.

331

332 **5. Acknowledgements**

333 The study was conducted under the Bill and Melinda Gates foundation funded ICTC-project
334 (Integrated Control of Taeniosis/Cysticercosis in sub-Saharan Africa). To all inhabitants of Mbeya
335 and Mbozi districts who agreed to participate and thereby made the study possible. To the field
336 team for all the hours spend in the field. To Drs Chummy Sikasunge and Kabemba Evans Mwape
337 from the University of Zambia for their technical assistance with the copro-Ag-ELISA assays.

338

339 **6. References**

340 Allan, J., Velasquez-Tohom, M., Garcia-Noval, J., Torres-Alvarez, R., Yurrita, P., Fletes, C., De
341 Mata, F., Soto, d.A.H., Craig, P., 1996. Epidemiology of intestinal taeniasis in four, rural,
342 Guatemalan communities. *Ann. Trop. Med. Parasitol.* 90, 157-165.

343 Allan, J.C., Avila, G., Noval, J.G., Flisser, A., Craig, P.S., 1990. Immunodiagnosis of taeniasis by
344 coproantigen detection. *Parasitology* 101, 473-477.

345 Allan, J.C., VelasquezTohom, M., Fletes, C., TorresAlvarez, R., LopezVirula, G., Yurrita, P.,
346 deAlfaro, H.S., Rivera, A., GarciaNoval, J., 1997. Mass chemotherapy for intestinal *Taenia solium*
347 infection: effect on prevalence in humans and pigs. *Trans. R. Soc. Trop. Med. Hyg.* 91, 595-598.

348 Braae, U., Saarnak, C., Mukaratirwa, S., Devleeschauwer, B., Magnussen, P., Johansen, M., 2015.
349 *Taenia solium* taeniosis/cysticercosis and the co-distribution with schistosomiasis in Africa. *Parasit.*
350 *Vectors.* 8, 323.

351 Braae, U.C., Magnussen, P., Lekule, F., Harrison, W., Johansen, M.V., 2014. Temporal fluctuations
352 in the sero-prevalence of *Taenia solium* cysticercosis in pigs in Mbeya Region, Tanzania. *Parasit.*
353 *Vectors.* 7, 574.

354 Carabin, H., Traoré, A.A., 2014. *Taenia solium* Taeniasis and Cysticercosis Control and
355 Elimination Through Community-Based Interventions. *Curr. Trop. Med. Rep.*, 1-13.

356 Cruz, M., Davis, A., Dixon, H., Pawlowski, Z.S., Proano, J., 1989. Operational studies on the
357 control of *Taenia solium* taeniasis/cysticercosis in Ecuador. *Bulletin of the World Health*
358 *Organization* 67, 401-407.

359 Diaz-Camacho, S.P., Ruiz, A.C., Peraza, V.S., Ramos, M.L.Z., Medina, M.F., Lozano, R., Willms,
360 K., 1991. Epidemiologic study and control of *Taenia solium* infections with praziquantel in a rural
361 village of Mexico. *Am J Trop Med Hyg* 45, 522-531.

362 Garcia, H.H., Gonzalez, A.E., Gilman, R.H., Moulton, L.H., Verastegui, M., Rodriguez, S.,
363 Gavidia, C., Tsang, V.C.W., Cysticercosis Working, G., 2006. Combined human and porcine mass
364 chemotherapy for the control of *T. solium*. *Am J Trop Med Hyg* 74, 850-855.

365 Gonzalez, A.E., Gilman, R., Garcia, H.H., McDonald, J., Kacena, K., Tsang, V., Pilcher, J.B.,
366 Suarez, F., Gavidia, C., Miranda, E., 1994. Use of sentinel pigs to monitor environmental *Taenia*
367 *solium* contamination. The Cysticercosis Working Group in Peru (CWG). *The American journal of*
368 *tropical medicine and hygiene* 51, 847-850.

369 Ilsoe, B., Kyvsgaard, N.C., Nansen, P., Henriksen, S.A., 1990. A study on the survival of *Taenia*
370 *saginata* eggs on soil in Denmark. *Acta Vet. Scand.* 31, 153-158.

371 Keilbach, N.M., De Aluja, A.S., Sarti-Gutierrez, E., 1989. A program to control taeniasis-
372 cysticercosis (*Taenia solium*): Experiences in a Mexican village. *Acta Leiden* 57, 181-190.

373 Komba, E.V., Kimbi, E.C., Ngowi, H.A., Kimera, S.I., Mlangwa, J.E., Lekule, F.P., Sikasunge,
374 C.S., Willingham III, A.L., Johansen, M.V., Thamsborg, S.M., 2013. Prevalence of porcine
375 cysticercosis and associated risk factors in smallholder pig production systems in Mbeya region,
376 southern highlands of Tanzania. *Vet. Parasitol.* 198, 284-291.

377 Kyvsgaard, N.C., Johansen, M.V., Carabin, H., 2007. Simulating transmission and control of
378 *Taenia solium* infections using a Reed-Frost stochastic model. *Int. J. Parasitol.* 37, 547-558.

379 Mwanjali, G., Kihamia, C., Kakoko, D.V.C., Lekule, F., Ngowi, H., Johansen, M.V., Thamsborg,
380 S.M., Willingham, A.L., 3rd, 2013. Prevalence and risk factors associated with human *Taenia*
381 *solium* infections in Mbozi district, Mbeya Region, Tanzania. *Plos Negl. Trop. Dis.* 7, e2102.

382 Mwape, K.E., Phiri, I.K., Praet, N., Muma, J.B., Zulu, G., Van den Bossche, P., de Deken, R.,
383 Speybroeck, N., Dorny, P., Gabriel, S., 2012. *Taenia solium* Infections in a Rural Area of Eastern
384 Zambia - A Community Based Study. *Plos Negl. Trop. Dis.* 6.

385 Ngowi, H.A., Carabin, H., Kassuku, A.A., Mlozi, M.R.S., Mlangwa, J.E.D., Willingham, A.L.,
386 2008. A health-education intervention trial to reduce porcine cysticercosis in Mbulu District,
387 Tanzania. *Prev. Vet. Med.* 85, 52-67.

388 Pawlowski, Z.S., 1991. Efficacy of low doses of praziquantel in taeniasis. *Acta Trop.* 48, 83-88.

389 Praet, N., Verweij, J.J., Mwape, K.E., Phiri, I.K., Muma, J.B., Zulu, G., van Lieshout, L.,
390 Rodriguez-Hidalgo, R., Benitez-Ortiz, W., Dorny, P., Gabriel, S., 2013. Bayesian modelling to
391 estimate the test characteristics of coprology, coproantigen ELISA and a novel real-time PCR for
392 the diagnosis of taeniasis. *Trop Med Int Health* 18, 608-614.

393 Sarti, E., Schantz, P.M., Avila, G., Ambrosio, J., Medina-Santillan, R., Flisser, A., 2000. Mass
394 treatment against human taeniasis for the control of cysticercosis: a population-based intervention
395 study. *Trans. R. Soc. Trop. Med. Hyg.* 94, 85-89.

396 URT, 2012. National Sample Census of Agriculture 2007/2008. Volume VI: Regional Report:
397 Mbeya Region, Tanzania: National Bureau of Statistics, pp. 1-326.

398 URT, 2013a. Population and Housing Census 2012 Report, Tanzania: National Bureau of Statistics,
399 pp. 1-244.


400 URT, 2013b. Population and Housing Census 2012 Report - Age & Sex Distribution, Tanzania:
401 National Bureau of Statistics, pp. 1-244.

402 URT, 2013c. Population and Housing Census 2012 Report - Village Statistics, Tanzania: National
403 Bureau of Statistics, pp. 1-244.

404 WHO, 2010. Working to overcome the global impact of neglected tropical diseases - First WHO
405 report on neglected tropical diseases, Geneva: World Health Organization.

406


407 **Figure legends:**



408 **Figure 1:** Schematic illustration of the study design with school-based mass drug administration
 409 (MDA) with praziquantel (40 mg/kg) to school-aged children (SAC) aged 4-15, ‘track and treat’ of

410 taeniosis positive people within the whole population, and three cross-sectional data collection
 411 points on taeniosis prevalence (R0 Feb/Mar 2012, R1 Jul/Aug 2013, and R2 July/Aug 2014).
 412

413



414

415 **Figure 2:** Taeniosis prevalence in school-aged children (SAC) aged 4-15, adults (>15), and both
 416 groups in the two districts Mbozi and Mbeya during the three cross-sectional surveys R0, R1, and
 417 R2. Asterisk (*) illustrates significant difference with baseline (R0) based on logistic regression
 418 with *p=0.01-0.05 and **p=0.001-0.009. The error bars depict the 95% binomial confidence
 419 intervals based on sample size and number of positives.

420

421 **Table legends:**

422 **Table 1:** Study population characteristics, and prevalence of taeniosis in the two districts Mbozi
 423 and Mbeya during the three surveys.

Survey	R0		R1		R2	
	Mbozi	Mbeya	Mbozi	Mbeya	Mbozi	Mbeya
Stool samples	1519 ^a	1510 ^b	1500 ^c	1521 ^d	1514	1500
Males %	50	50	52	48	46	45
Females %	51	49	48	52	54	55
Children (4-15)	951	880	712	1098	1255	1400
Adults (16-87)	561	621	786	422	259	100
Taeniosis (%)	45 (3.0)	22 (1.5)	30 (2.0)	5 (0.3)	12 (0.8)	8 (0.5)
Taeniosis in children (%)	22 (2.3)	11 (1.3)	2 (0.3)	2 (0.2)	7 (0.6)	8 (0.6)
Taeniosis in adults (%)	23 (4.1)	11 (1.8)	28 (3.6)	3 (0.7)	5 (1.9)	0 (0.0)

424 ^aSex was not recorded for 7 individuals

425 ^bSex was not recorded for 9 individuals

426 ^cSex was not recorded for 2 individuals

427 ^dSex was not recorded for 1 individual

428

Taeniosis

Porcine cysticercosis

